John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 50,000 shares at $22.37 ($1.1M) on 2026-03-30, disclosed to the SEC on 2026-04-01.
Scheduled sale ($1.1M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.37 | 25,000 | $559K | 49.6% |
| 2 | $22.76 | 25,000 | $569K | 50.4% |
| Total | $22.57 avg | 50,000 | $1.1M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-06 | $739K | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |